JAK/STAT in Fibrosis: Inflammation via JAK Inhibitors

Introduction: Why JAK/STAT Bridges "Inflammation → Fibrosis"

"From inflammation to fibrosis"—this transition is the essence of chronic disease. While the NF-κB pathway drives initial inflammasome activation, the JAK/STAT pathway functions downstream as the hub of cytokine signaling.

Many cytokines involved in both inflammation and fibrosis—IL-6, IFN-γ, IL-13, GM-CSF—act through the JAK/STAT pathway. Efforts to repurpose JAK inhibitors approved for rheumatoid arthritis and myelofibrosis toward antifibrotic applications are progressing, offering an intervention point distinct from TGF-β and Wnt.

---

1. Molecular Mechanism of JAK/STAT Signaling

JAK Family: Four Tyrosine Kinases

Mammals have four JAKs (Janus Kinases):

JAK	Associated Cytokine Receptors	Relevance to Fibrosis
JAK1	IL-6 family, IFN-α/β, IFN-γ, IL-2 family	Most broad
JAK2	IL-3, GM-CSF, EPO, GH, prolactin, IFN-γ	Critical in myelofibrosis
JAK3	γc chain (IL-2, 4, 7, 9, 15, 21)	Immune system
TYK2	IL-12, IL-23, IFN-α/β	Autoimmunity, fibrosis involvement

STAT Family: Seven Transcription Factors

There are seven STATs (Signal Transducers and Activators of Transcription), each responding to specific cytokines:

• STAT1: IFN-γ, IFN-α/β response. Both antifibrotic (Th1-type) and inflammatory roles
• STAT3: IL-6, IL-10, IL-17 response. Major mediator of fibrosis promotion
• STAT4: IL-12, Th1 differentiation
• STAT5 (5a/5b): IL-2, IL-3, GM-CSF, PRL. Tregs, myeloid cells
• STAT6: IL-4, IL-13 response. Key factor in M2 macrophages and Th2-type fibrosis

Standard Activation Steps

1. Ligand binding: Cytokine binds receptor; receptor chains dimerize
2. JAK activation: Receptor-associated JAKs are activated via mutual phosphorylation
3. Receptor phosphorylation: Activated JAKs phosphorylate receptor intracellular domains
4. STAT recruitment and phosphorylation: STATs bind phosphotyrosine via SH2 domain and are phosphorylated by JAKs
5. Dimerization and nuclear translocation: STATs form homo/heterodimers and translocate to the nucleus
6. Target gene transcription: Bind GAS (Gamma-Activated Site) or ISRE sequences to induce gene expression

---

2. Two Major Roles: STAT3 and STAT6 in Fibrosis

STAT3: Central Mediator of Fibrosis Promotion

The IL-6/JAK1/STAT3 axis is the most studied in fibrosis research.

• Activation pathway: IL-6, IL-11, IL-22 phosphorylate STAT3 via JAK1
• Target genes: Col1a1, α-SMA, CTGF, and TGFβ1 itself
• Hepatic stellate cell (HSC) activation: IL-6/STAT3 differentiates HSCs into myofibroblasts
• Cardiac fibrosis: IL-11 activates cardiac fibroblasts via STAT3 (Schafer et al., Nature, 2017)
• Lung fibroblasts: High phospho-STAT3 expression in IPF fibroblast foci

STAT6: The Main Actor in Th2-Type Fibrosis

The IL-4/IL-13/STAT6 axis is important in asthma, IPF, and post-parasitic fibrosis.

• Activation pathway: IL-4, IL-13 phosphorylate STAT6 via JAK1/JAK2/JAK3
• M2 macrophage polarization: STAT6 induces M2 markers Arg1, Ym1, Fizz1. M2 macrophages secrete TGF-β and PDGF to drive fibrosis
• Airway remodeling: Promotes airway smooth muscle hypertrophy and mucin overproduction in asthma
• Parasite infection models: STAT6 is essential for hepatic granuloma formation in Schistosoma infection

For details on macrophage polarization, see Fundamentals of Macrophage Polarization.

---

3. STAT1: Balance Between Antifibrotic and Inflammatory

STAT1 works in an "antifibrotic" direction distinct from STAT3/STAT6.

• IFN-γ/STAT1: Th1 cytokine signaling. M1 macrophage polarization, suppression of collagen production in fibroblasts
• Clinical history: IFN-γ was once considered for IPF treatment but discontinued after large trials (INSPIRE) showed no efficacy
• STAT1/STAT3 balance: The balance of STAT1 and STAT3 in the same tissue determines the direction of fibrosis

---

4. Crosstalk with Other Pathways

Crosstalk with TGF-β/Smad

The TGF-β pathway and JAK/STAT have bidirectional interaction:

• TGF-β induces IL-6 secretion → STAT3 activation → enhanced α-SMA expression
• STAT3 directly enhances Smad3 transcriptional activity
• JAK inhibitors also suppress expression of some TGF-β downstream genes

Crosstalk with NF-κB

• Both NF-κB and STAT3 are involved in IL-6 production (inflammation→fibrosis positive feedback)
• STAT3 regulates chromatin accessibility of NF-κB target genes

Relationship with Hippo/YAP-TAZ

• Nuclear YAP/TAZ activity cooperates with STAT3 to induce fibrosis genes
• Tissue stiffening → YAP/TAZ activation → IL-6 secretion → STAT3 activation positive feedback

---

5. JAK Inhibitors as Therapeutic Targets

Approved JAK Inhibitors and Indications

Compound	Target	Main Approved Indications	Antifibrotic Preclinical/Clinical Data
Ruxolitinib	JAK1/2	Myelofibrosis, polycythemia vera, GVHD	Effective in myelofibrosis; exploratory trials in skin scleroderma and IPF
Tofacitinib	JAK1/3	RA, UC, psoriatic arthritis	Clinical trials in scleroderma and SSc-ILD
Baricitinib	JAK1/2	RA, COVID-19, atopic dermatitis	Preclinical efficacy in renal and skin fibrosis
Upadacitinib	JAK1	RA, UC, atopic dermatitis	Higher selectivity with improved side-effect profile
Fedratinib	JAK2	Myelofibrosis	JAK2-specific

Disease-Specific Antifibrotic Applications

Myelofibrosis (PMF) Ruxolitinib has been shown to suppress bone marrow fibrosis progression, particularly in JAK2-mutated cases (COMFORT-I/II). This is the most established evidence for the antifibrotic effect of JAK inhibitors.

Scleroderma (SSc) and SSc-ILD Small trials of Tofacitinib and Baricitinib have reported improvements in modified Rodnan skin score (mRSS) and FVC. Also see Antifibrotic Drug Pipeline.

IPF Small Ruxolitinib trials are ongoing but large-scale evidence remains limited. Next-generation approaches targeting IL-11/STAT3 (anti-IL-11 antibodies) are gaining attention.

Renal fibrosis Preclinical models such as UUO have shown JAK inhibition suppresses collagen deposition and myofibroblast differentiation.

Evolution of Selectivity: From pan-JAK to Selective

Early JAK inhibitors (Tofacitinib, Ruxolitinib) were pan-JAK with side effects including infections, anemia, and thrombosis. Recently, TYK2-selective inhibitors (Deucravacitinib) and JAK1-selective inhibitors (Upadacitinib, Filgotinib) have emerged with improved safety profiles.

---

6. Practical Preclinical Evaluation

Markers to Measure

• Phospho-STAT3 (pY705): Most sensitive marker of IL-6 signaling activity
• Phospho-STAT6 (pY641): IL-4/13 signaling
• Target gene expression: SOCS3 (STAT3 feedback suppressor), Arg1 (STAT6 target)
• Macrophage polarization: M1/M2 ratio, Arg1/iNOS ratio
• Tissue fibrosis: hydroxyproline, Sirius Red, α-SMA IHC

Recommended Models

• Bleomycin pulmonary fibrosis: IL-6/STAT3 axis validation
• CCl4 liver fibrosis: Kupffer cell/HSC activation
• UUO renal fibrosis: STAT3-dependent tubular atrophy
• Schistosoma liver fibrosis: Gold standard for STAT6-dependent Th2-type fibrosis

---

Conclusion

The JAK/STAT pathway is the "cytokine hub" in the transition from inflammation to fibrosis, interacting with major pathways like TGF-β, NF-κB, and YAP/TAZ to drive fibrosis. Expanding antifibrotic indications for already-approved JAK inhibitors is a promising path, but improved selectivity and side-effect management are key.

For next-generation approaches, more refined intervention strategies—IL-11-specific inhibition, direct STAT3 inhibition, TYK2-selective inhibition—will become the focus of clinical development.

---

Related Articles

• TGF-β/Smad Pathway: The Master Switch of Fibrosis
• NF-κB Pathway: Strategies to Stop Chronic Inflammation Without Promoting Fibrosis
• Wnt/β-catenin: Why a Developmental Pathway Drives Fibrosis
• YAP/TAZ Mechanotransduction
• Fundamentals of Macrophage Polarization
• Antifibrotic Drug Pipeline 2025

---

References

1. O'Shea JJ, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311-328.
2. Schafer S, et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature. 2017;552(7683):110-115.
3. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
4. Milara J, et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):24.
5. Wang S, et al. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. PNAS. 2013.